A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1085 participants.
Also called NCT04760626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,085 participants
- Sponsor
- Registry
-
NCT04760626 -
2020-000476-38
-
- Other papers using this trial's data
- Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Germany, Greece, Hungary, Poland, Puerto Rico, Serbia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT04760626. Randomized; no masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2022-08-12 (actual). Results posted on 2025-08-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Acronym
- ONWARDS 5
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Insulin Glargine 100U/mL
- Intervention (Drug)
- Insulin Degludec
- Intervention (Drug)
- Insulin Glargine 300U/mL
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04760626- Content hash
a70e6fbed87a4145c90d117d0667af3f9e1ebb0160e9d55fdf4adcccbcd9a867